{"id":"W4211012592","doi":"10.1136/annrheumdis-2021-221478","title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":true,"ca_institutions":"Seagen (Canada)","funders":"AstraZeneca","keywords":"Medicine; Lupus nephritis; Systemic lupus erythematosus; Internal medicine; Immunology; Lupus erythematosus; Antibody; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003426931,0.002046194,0.003317382,0.000355296,0.0004266682,0.001115982,0.0008889058,0.001903373,0.007507365],"category_scores_gemma":[0.002961282,0.0009631958,0.001570606,0.0003504924,0.001109206,0.001029882,0.0004302643,0.002951144,0.001219792],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007634036,"about_ca_system_score_gemma":0.001374885,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006873358,"about_ca_topic_score_gemma":0.001524603,"domain_scores_codex":[0.9987722,0.0007752905,0.00007738431,0.0001797894,0.00007478816,0.0001205157],"domain_scores_gemma":[0.9981748,0.0006067868,0.0004639155,0.0001403831,0.0001273908,0.0004866299],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9849918,0.0042881,0.0005280104,0.00032039,0.0004873519,0.00003244863,0.00003233125,0.0001786882,0.001675226,0.00004231999,0.0004916007,0.006931789],"study_design_scores_gemma":[0.9611002,0.03721672,0.0008433223,0.00001501956,0.0001225414,0.00002385837,0.00000744967,0.0001743548,0.000142615,0.0000431419,0.0003045109,0.000006279926],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9773179,0.005290784,0.00125613,0.0009048181,0.00115662,0.01022612,0.001391346,0.0001316873,0.002324534],"genre_scores_gemma":[0.9748184,0.002779173,0.002571285,0.002298993,0.001096475,0.0104614,0.001442748,0.00003089011,0.004500519],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007507365,"threshold_uncertainty_score":0.0251146,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02840189127958469,"score_gpt":0.3146021011149681,"score_spread":0.2862002098353834,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}